Navigation Links
New Proton Therapy Equipment Enables More Tumors to be Treated
Date:2/23/2009

JACKSONVILLE, Fla. Feb. 23 /PRNewswire/ -- An advance in the way protons are delivered at the University of Florida Proton Therapy Institute enables physicians to treat tumors that are deeper in the body, tumors that are very large and tumors that are situated closer to vital organs.

Called uniform scanning, the new device moves a single beam of protons in a sweeping or "scanning" motion, enabling the beam to reach deeper into the body and to cover a wider treatment area than the more commonly used scattering method. Until now the proton beam was "scattered" and flattened using round filters that limited how deep and how wide protons could travel into the body.

Proton therapy will now be a possible treatment option for prostate cancer patients with a hip circumference of more than 50 inches and for sarcoma patients with tumors larger than 9.4 inches. Uniform scanning also means significant medical advantages for patients with tumors in the head and neck, brain or spinal column since it can cover the target area more efficiently than the scattering method.

"With proton therapy, our ability to precisely deliver radiation to the tumor without damaging normal healthy tissue is the main advantage for all patients," said Dr. Nancy Mendenhall, UF Proton Therapy Institute's medical director. "Uniform scanning takes us to the next step in improving delivery of protons, eventually leading to more intense and fewer doses and the potential to further decrease risk of complications."

The technology was developed over the past four years by IBA in collaboration with Massachusetts General Hospital and the UF Proton Therapy Institute. IBA is the leading manufacturer of particle therapy equipment, with international headquarters in Belgium and a United States proton therapy headquarters in Jacksonville.

"The immediate advantages of uniform scanning are evident in the increased number of patients and types of tumors we will be able to treat," said Dr. Zuofeng Li, UF Proton Therapy Institute's director of physics. "Over time, we expect additional clinical advantages to emerge."

UF Proton Therapy Institute is a nonprofit 501(c)3 organization affiliated with the UF College of Medicine and the UF Shands Cancer Center, national leaders in cancer treatment and research. UF Proton Therapy Institute is dedicated to delivering state-of-the-art cancer treatment and strives to set new standards for treating and curing the disease. The cancer treatment facility houses both conventional radiation and proton therapy, and delivers proton therapy to more than 100 patients a day. For more information about UF Proton Therapy Institute, please visit www.floridaproton.org, or call toll-free 877-686-6009.

ABOUT IBA:

IBA develops and markets leading edge technologies, pharmaceuticals and tailor-made solutions for healthcare with a focus on cancer diagnosis and therapy. Leveraging on its scientific expertise, IBA is also active in the field of industrial sterilization and ionization. Listed on the pan-European stock exchange EURONEXT, IBA is included in the BelMid Index.

(IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). Website: http://www.iba-worldwide.com


'/>"/>
SOURCE University of Florida Proton Therapy Institute
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Progesterone Therapy and Preterm Birth: More Evidence Helps Identify Women Who Can Benefit
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
6. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
7. St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia
8. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
9. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
10. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Md. , March 23, 2017  The U.S. ... Bavencio (avelumab) for the treatment of adults and pediatric ... carcinoma (MCC), including those who have not received prior ... MCC, a rare, aggressive form of skin cancer. ... common cancers, patients with a rare form called Merkel ...
(Date:3/23/2017)... VANCOUVER, British Columbia , March 23, ... ) (the "Company" or "Sophiris"), a clinical late-stage biopharmaceutical ... diseases, today announced that data from its successful Phase ... a focal treatment for localized prostate cancer, will be ... the 32 nd Annual European Association of Urology ...
(Date:3/23/2017)... -- Research and Markets has announced the addition of ... their offering. ... The global oxygen therapy devices market to grow at a CAGR ... Global Oxygen Therapy Devices Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
Breaking Medicine Technology:
(Date:3/23/2017)... Kennett Square, PA (PRWEB) , ... March 23, 2017 , ... ... sunny days. That means many students are thinking about summer internships , which ... (or lack thereof). , The pros at Garden Media Group, a boutique public relations ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... products at competitive pricing. Verisys through its FACIS and other ... restrictions and Disciplinary actions. , “We are delighted to be able to offer ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... stands with all Americans facing life-altering and fatal diseases in opposition to the ... shortsighted decisions that would eviscerate care, services, and hope for the most vulnerable ...
(Date:3/23/2017)... ... March 23, 2017 , ... On ... Dagger Foundation the US Special Operations Command’s Patriot Award. The award was presented ... thanked Task Force Dagger Foundation for its significant and enduring support to the ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... The Boulevard ... 10am - 2pm. All events will be located in the Main West Entrance ... a no-cost Child ID event. No appointment is necessary and each child with a ...
Breaking Medicine News(10 mins):